Slide 1

Slide 1 text

11/11/2016 1 Gustavo Waclawovsky Beatriz D. Schaan

Slide 2

Slide 2 text

11/11/2016 2 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 3

Slide 3 text

11/11/2016 3 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 4

Slide 4 text

11/11/2016 4 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 5

Slide 5 text

11/11/2016 5 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 6

Slide 6 text

11/11/2016 6 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 7

Slide 7 text

11/11/2016 7 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653.

Slide 8

Slide 8 text

11/11/2016 8 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653. Flow Mediated Dilatation (%) Control Microalbuminuria Normoalbuminuria Type 1 Diabetes

Slide 9

Slide 9 text

11/11/2016 9 Type 1 Diabetes (T1DM) Mortality from Ischemic Heart Disease Atherosclerosis Endothelial dysfunction CD34+ CD45dim KDR+ Endothelial progenitor cells Replaces endothelial cells injured Laing SP et al. Diabetologia 2003;46:760-5. Cé GV. J Clin Endocrinol Metab 2011;96:1493-9. Hörtenhuber T. Diabetes Care 2013, 36:1647–1653. CD34+/CD133+/KDR+ (Cells/ 1x106 WBC) Control T1DM

Slide 10

Slide 10 text

11/11/2016 10 Fuchsjager-Mayrl G. et al. Diabetes Care 25:1795–1801, 2002. • Bike; • 40 min; • 60-70% HR reserve; • 3 x week. • Bike; • 30 min; • 80% VO2max; • Blood: 20 min. Cubbon RM et al. Arterioscler Thromb Vasc Biol. 2010;30:878-884. Aerobic Exercise: endothelial function in T1DM and progenitor cells in healthy subjects Before training After 4 months * P<0,05 Flow-mediated dilation (% change) * P<0,05 CD34+ CD34+/KDR+

Slide 11

Slide 11 text

11/11/2016 11 To evaluate the acute effect of aerobic exercise (AE) and resistance exercise (RE) on the release of endothelial progenitor cell (EPCs, CD34+/KDR+/CD45dim) and vascular function in T1DM. Purpose Hypothesized Aerobic and resistance exercises would induce a rise in circulating EPCs but lower in patients with diabetes when compared with healthy controls.

Slide 12

Slide 12 text

11/11/2016 12 Crossover Clinical Trial T1 DM (n= 14) Healthy subjects (n= 5) Aerobic exercise Resistance exercise Methods Inclusion criteria: • Male sex, • ≥ 18 years old; • Without regular exercise. Exclusion criteria: • Severe autonomic neuropathy; • Diabetic nephropathy; • End stage renal disease; • Disabling peripheral arterial disease; • Proliferative diabetic retinopathy; • Coronary artery disease; • Heart failure; • Limb amputation; • Cancer; • Smoking. randomization (7 days) Cardiopulmonary exercise testing Maximal strength testing (1-RM)

Slide 13

Slide 13 text

11/11/2016 13 4 lower-limb exercises; 4 x 12 repetitions; 60% 1-RM; 90 sec (between sets and exercises); 2 sec/phase (concentric and eccentric). 2) Kneed flexion 1) Knee extension 3) Leg press 4) Calf press Resistance exercise session

Slide 14

Slide 14 text

11/11/2016 14 4 lower-limb exercises; 4 x 12 repetitions; 60% 1-RM; 90 sec (between sets and exercises); 2 sec/phase (concentric and eccentric). 2) Kneed flexion 1) Knee extension 3) Leg press 4) Calf press Cycle ergometer; 60% VO2peak ; Heart rate monitor and Borg scale 6 to 20. Resistance exercise session Aerobic exercise session

Slide 15

Slide 15 text

11/11/2016 15 4 lower-limb exercises; 4 x 12 repetitions; 60% 1-RM; 90 sec (between sets and exercises); 2 sec/phase (concentric and eccentric). • 40 min; • Capillary blood glucose (Baseline and every 10 min); • Glucose levels > 150 mg.dL-1 and e < 250 mg.dL-1. 2) Kneed flexion 1) Knee extension 3) Leg press 4) Calf press Cycle ergometer; 60% VO2peak ; Heart rate monitor and Borg scale 6 to 20. Resistance exercise session Aerobic exercise session

Slide 16

Slide 16 text

11/11/2016 16 Flow cytometer (FACSCalibur, BD Biosciences) Progenitor cells (10 min before and 10 min after): • CD34+/CD45dim • CD34+/KDR+/CD45dim 20-mL Analyses

Slide 17

Slide 17 text

11/11/2016 17 Venous occlusion plethysmography (DE Hokanson) • Blood flow (10 min before and 5 min after) Vascular resistance (10 min before and 5 min after) • Reactive hyperemia (10 min before and 10 min after) Flow cytometer (FACSCalibur, BD Biosciences) Progenitor cells (10 min before and 10 min after): • CD34+/CD45dim • CD34+/KDR+/CD45dim 20-mL Analyses

Slide 18

Slide 18 text

11/11/2016 18 Results

Slide 19

Slide 19 text

11/11/2016 19 Results

Slide 20

Slide 20 text

11/11/2016 20 Results

Slide 21

Slide 21 text

11/11/2016 21 Results

Slide 22

Slide 22 text

11/11/2016 22 Results

Slide 23

Slide 23 text

11/11/2016 23 Progenitor cells Endothelial progenitor cells * P < 0,05 vs. versus baseline in the same group; † P < 0,05 vs. versus after RE session (group-session interaction); ‡ P < 0,05 vs. versus after AE exercise session. Mean ± SEM; GEE for repeated adjusted for baseline values.

Slide 24

Slide 24 text

11/11/2016 24 Forearm blood flow Forearm vascular resistance * P < 0,05 vs. versus baseline in the same group; ‡ P < 0,05 vs. versus after AE exercise session. Mean ± SEM; GEE for repeated adjusted for baseline values.

Slide 25

Slide 25 text

11/11/2016 25 Forearm reactive hyperemia * P < 0,05 vs. versus baseline in the same group; Mean ± SEM; GEE for repeated adjusted for baseline values.

Slide 26

Slide 26 text

11/11/2016 26 SUMMARY • Exercise did not induce changes in the levels of EPCs in patients with T1DM; • In controls, EPCs were decreased after AE (- 10.7 %, P = 0.017) and increased after RE (+ 12.2 %, P = 0.004); • Blood flow increased and vascular resistance decreased after RE in both groups; • Reactive hyperemia was increased 10 min after AE and RE sessions in patients with T1DM (36.5% and 42.0%, respectively) and in controls (35.4% and 74.3%), but no differences were observed between groups in response to exercise.

Slide 27

Slide 27 text

11/11/2016 27 Conclusions The unchanged EPC number in patients with DM1 after exercise sessions may reveal impaired capacity for endothelium regeneration and consequent early deterioration which was not observed by vascular parameters used.

Slide 28

Slide 28 text

11/11/2016 28 Gustavo Waclawovsky Beatriz D’ Schaan Obrigado! [email protected] [email protected] FIPE